AnaptysBio (ANAB) Q2 Revenue Jumps 103%
(NASDAQ:ANAB), a clinical-stage biotechnology company focused on innovative immunology therapeutics for autoimmune and inflammatory diseases, released its Q2 2025 earnings on August 6, 2025. The company reported $22.3 million in collaboration revenue in Q2 2025, more than doubling from $11.0 million in collaboration revenue in Q2 2024 and exceeding analyst estimates by $10.62 million. GAAP earnings per share were $(1.34) in Q2 2025, which was better than the estimated $(1.55) GAAP loss and an improvement over last year's $(1.71) GAAP loss per share. The company’s performance was driven by stronger-than-expected royalty revenue from its outlicensed products. Overall, the quarter’s results present meaningful progress on AnaptysBio’s pipeline and partnerships, even as losses and cash usage remain considerable.
Source: Analyst estimates for the quarter provided by FactSet.
AnaptysBio develops innovative antibody therapies for autoimmune and inflammatory diseases. Its business revolves around discovering and advancing engineered antibodies, with a current pipeline that includes rosnilimab, ANB033, and ANB101, each targeting different immune-related pathways.
Source Fool.com
AnaptysBio Inc Stock
With 21 Buy predictions and not a single Sell prediction AnaptysBio Inc is an absolute favorite of our community.
As a result the target price of 38 € shows a positive potential of 38.69% compared to the current price of 27.4 € for AnaptysBio Inc.
